Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Enanta Pharmaceuticals Inc
9EPCurrent price
9.3 EUR
-0.3 EUR (-3.13%)
Last closed
10.43 USD
Company
www.enanta.com
ISIN
US29251M1062
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
234 557 792 USD
Yield for 12 month
+15.77 %
1Y
3Y
5Y
10Y
15Y
9EP
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts. Address: 500 Arsenal Street, Watertown, MA, United States, 02472
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
21 USDP/E ratio
–Dividend Yield
–Current Year
+79 204 000 USD
Last Year
+86 160 000 USD
Current Quarter
+17 971 000 USD
Last Quarter
+17 054 000 USD
Current Year
+76 833 000 USD
Last Year
+83 187 000 USD
Current Quarter
+17 377 000 USD
Last Quarter
+16 433 000 USD
Key Figures 9EP
1 year
3 years
5 years
10 years
EBITDA
-120 341 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-17.18 %
PEG Ratio
–
Return On Equity TTM
-59.64 %
Wall Street Target Price
21 USD
Revenue TTM
71 960 000 USD
Book Value
7.03 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-4.9 %
Dividend Yield
–
Gross Profit TTM
86 160 000 USD
Earnings per share
-5.45 USD
Diluted Eps TTM
-5.45 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
-66.2 %
Profit Margin
-160.27 %
Dividend Analytics 9EP
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 9EP
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 9EP
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
0.7649
Price Sales TTM
3.2596
Enterprise Value EBITDA
-0.291
Price Book MRQ
1.5751
Financials 9EP
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 9EP
For 52 weeks
8.4 USD
17.8 USD
50 Day MA
11.55 USD
Shares Short Prior Month
2 985 735
200 Day MA
13.16 USD
Short Ratio
16.53
Shares Short
3 427 004
Short Percent
17.2 %
BeatStart